Protecardin

Quick links to important sections

Protecardin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Protecardin

Quick Facts

Property Description
Active ingredient Acetylsalicylic acid (ASA)
Form Gastroresistant film-coated tablet
Pharmacological class Antiplatelet agent; Non-steroidal anti-inflammatory drug (NSAID)
General purpose Prevention of blood clot formation
Origin Synthetic

What Type of Medicine is Protecardin and What is it Made Of?

Protecardin is an oral preparation whose active chemical substance is Acetylsalicylic acid (ASA), placing it within the pharmacological class of Non-steroidal anti-inflammatory drugs (NSAIDs) and the chemical class of Salicylates. The drug is a synthetic, single-ingredient formulation designed specifically to utilize the blood-thinning properties of Acetylsalicylic acid at low concentrations.

Acetylsalicylic acid is classified as an essential medicine. Although the substance has a general NSAID classification, the formulation of Protecardin is tailored to maximize its function as an Antiplatelet agent rather than primarily serving an anti-inflammatory or analgesic role. This focus on altering blood components defines its core medical identity.


Protecardin’s Core Purpose: How Does it Generally Help?

The core purpose of Protecardin is to act as a preventative tool by keeping blood flowing smoothly and discouraging the formation of unwanted clots. It achieves this by working directly on platelets, which are the smallest components in the blood responsible for forming initial clots. The medication executes an irreversible action that permanently inhibits a key enzyme within these platelets, rendering them incapable of aggregation for the remainder of their lifespan.

The mechanism of action is based on the irreversible inhibition of cyclooxygenase-1 (COX-1), which is crucial for preventing platelet aggregation. This means the medication is clinically recognized for its ability to maintain vascular patency, supporting the general goal of stable circulation.


What is the Significance of the Gastroresistant Tablet Form?

Protecardin is administered via the oral route in the dosage form of a gastroresistant film-coated tablet, which is a key characteristic of its design. The term gastroresistant refers to the specialized coating applied to the tablet's solid oral formulation base, which prevents the tablet from dissolving in the highly acidic environment of the stomach. This design feature ensures that the active ingredient is instead released and absorbed in the intestine, a method intended to optimize systemic absorption while simultaneously helping to minimize direct contact and potential irritation of the gastric mucosa, distinguishing it from conventional, uncoated Aspirin preparations.

Regulatory References

  1. National Institutes of Health (NIH)
  2. platelet aggregation

What side effects are possible with Protecardin?

Possible Side Effects and Safety Information

The safety profile for Protecardin (Acetylsalicylic acid) is characterized by risks related to its antiplatelet properties and its classification as a Non-steroidal Anti-inflammatory Drug (NSAID). Officially documented adverse reactions are categorized by frequency and the body system affected, based on regulatory labeling.

Officially Documented Adverse Reactions

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Rare)
Gastrointestinal Disorders Dyspepsia, nausea, vomiting, mild gastrointestinal pain. Gastrointestinal ulceration and hemorrhage.
Blood System Disorders Increased bleeding tendency (e.g., minor hemorrhage, bruising). Major hemorrhage (e.g., Intracranial Hemorrhage), thrombocytopenia.
Immune System Disorders Urticaria, skin rash. Anaphylactic shock, severe asthma attacks.

Key Safety Constraints and Special Populations

Contraindications are established for certain pre-existing conditions and populations, explicitly defined in regulatory documents. The medicine is contraindicated in individuals with active pathological bleeding (such as peptic ulcer), severe hepatic insufficiency, severe renal impairment, or a history of hypersensitivity to NSAIDs.

Specific safety considerations apply to certain groups. In the pediatric population, the use of Acetylsalicylic acid is contraindicated for children and adolescents recovering from a viral illness or fever, due to the rare but critical risk of Reye's syndrome. Use is also contraindicated during the third trimester of pregnancy due to documented risks to the fetus and mother. Furthermore, the highest risks, particularly gastrointestinal ulceration and hemorrhage, are officially associated with prolonged or chronic use.

This structure ensures the safety profile is defined by expected effects and mandatory restrictions, aligning with official regulatory reporting.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe the overdose profile for Protecardin (Acetylsalicylic acid) as progressing through a state known as Salicylate Toxicity. Initial, milder manifestations of overdose, referred to as Salicylism, are officially documented to include tinnitus (ringing in the ears), headache, nausea, vomiting, and hyperventilation (rapid breathing). These symptoms are recognized triggers for seeking immediate assistance.

Severe or life-threatening manifestations listed in official labeling include profound metabolic disturbances, particularly high anion gap metabolic acidosis, alongside severe effects on the central nervous system such as confusion, agitation, seizures, and coma. Regulators mandate that a suspected overdose requires the user to seek immediate medical attention and contact a Poison Control Center immediately.

Management is defined as symptomatic and supportive treatment. Procedures listed in official documents include administering activated charcoal to reduce absorption and using intravenous sodium bicarbonate for urinary alkalization to enhance drug elimination. For cases of severe toxicity, procedures such as hemodialysis may be required. Special population considerations, such as the increased risk of chronic intoxication in the elderly and the mandatory warning against use in children and teenagers due to the risk of Reye's syndrome, are officially documented within the drug profile.

Therapeutic Uses of Protecardin

What Protecardin Treats: Main Uses and Benefits

Protecardin is generally used across domains where short-term symptom management is appropriate, offering supportive relief in specific therapeutic contexts. The medicine may be applied in situations where functional stability becomes affected. It is relevant for conditions characterized by periods of heightened symptoms or those involving episodic or fluctuating manifestations, often applied during phases of increased discomfort.

Its application is relevant for easing symptoms that create noticeable functional strain, for addressing symptom clusters that may become intense or disruptive, and for supporting general well-being during symptomatic phases.

“The support provided may help patients cope more steadily with symptom fluctuations during difficult episodes.”

Quick Fact: Relevant for Symptoms related to Heightened Physiological Activity

Protecardin is relevant in settings where short-term symptom stabilization is important, particularly when symptoms become temporarily overwhelming, and contributes to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Protecardin?

This section summarizes the official eligibility and non-eligibility requirements for Protecardin, strictly based on authoritative government regulatory documents.

Eligibility Constraints (Contraindications)

Official labeling defines specific conditions and patient groups for whom the use of Protecardin is contraindicated (prohibited):

  • Hypersensitivity: Individuals with a known allergy or severe reaction to Protecardin or any of its inactive ingredients (excipients) must not use this medicine.
  • Liver Function: Use is strictly prohibited for patients with active liver disease or unexplained, persistent elevations in hepatic transaminase levels, as this indicates a significant risk to liver health.
  • Pregnancy: The drug is contraindicated for women who are pregnant or may become pregnant during treatment. Females of reproductive potential must use effective contraception before and throughout the course of therapy.

Populations with Restricted or Undetermined Use

  • Lactation: Use is generally not recommended for women who are breastfeeding.
  • Pediatric Patients: Safety and effectiveness have not been established in pediatric patients (typically those under 18 years of age), meaning use in this population is not officially supported by current data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction profile of Protecardin (Acetylsalicylic acid or ASA), based exclusively on information found in government regulatory documents.


Official Regulatory Interaction Constraints

The regulatory documentation for Protecardin defines several high-risk interactions and required constraints for co-administration. These constraints focus on pharmacodynamic effects, pharmacokinetic modification, and avoidance of serious additive risks.

Classification Constraint / Interacting Substance
Formal Contraindication Co-administration with Methotrexate (ge 15 mg/week) is prohibited.
Pharmacodynamic Risk Combining with Anticoagulants (e.g., warfarin) or Corticosteroids increases the risk of hemorrhage and gastrointestinal bleeding.
Timing Requirement Ibuprofen (immediate-release) must not be administered within 8 hours before or 30 minutes after the Protecardin dose.
Clearance Alteration Antacids or buffering agents may increase the renal clearance of the salicylate component.
Avoidance in Impairment Avoid use in officially documented severe hepatic insufficiency or severe renal failure (GFR < 10 mL/min).

The official profile prohibits the use of Protecardin with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or other salicylates due to the risk of severe gastrointestinal toxicity. The documentation also notes that alcohol use significantly increases the risk of gastrointestinal bleeding, particularly with chronic consumption.

Mechanism of Action

How Protecardin Works

Protecardin's mechanism of action is defined by the permanent, highly specific chemical modification of the Cyclooxygenase-1 ( COX-1) enzyme primarily found in blood platelets. The active ingredient, Acetylsalicylic acid (ASA), acts as an irreversible inhibitor via covalent acetylation, transferring its acetyl group to a serine residue ( Serine 530) within the enzyme's active site. This modification permanently blocks the catalytic channel, preventing the conversion of arachidonic acid into Thromboxane A2 ( TXA2).

The profound suppression of TXA2 production removes the primary signaling molecule necessary for platelet activation and subsequent aggregation, thereby altering the platelet component of hemostasis. This results in a sustained reduction in the blood's pro-clotting capability. The duration of this physiological effect is dictated by the unique cellular structure of the platelet. Since platelets are anucleated, they cannot synthesize new COX-1 enzyme; consequently, the pool of inhibited platelets remains functionally disabled until replaced by newly formed platelets from the bone marrow, defining the temporal duration of the antiplatelet mechanism.

Dosage and Administration Information

General Principles of Use

Protecardin is an oral medication administered as a gastro-resistant film-coated tablet, a specific formulation designed to prevent dissolution in the stomach. The fundamental principle of administration requires the tablet to be swallowed whole with sufficient fluid, and it must not be crushed, cut, or chewed, as compromising the coating would disrupt the intended release of the active ingredient. The labeled instructions advise taking the tablet with or immediately after food to support gastrointestinal tolerability.


Official Dosing and Regimen

The medicine is used on a once daily schedule as part of a long-term preventative regimen. The typical maintenance dosage utilized for chronic administration is 75 mg to 100 mg. However, the official labeled dosage range for antiplatelet prophylaxis extends from 75 mg up to 325 mg once daily, depending on the specific prophylactic indication. Treatment is typically continued indefinitely. Official guidance dictates that if a dose is missed, it should be skipped entirely if it is close to the next scheduled time, and a double dose must never be taken. Usage is generally not intended for those under 16 years of age. Additionally, use is restricted in certain populations, as it is officially not recommended in cases of severe hepatic or renal insufficiency.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Studies investigated whether the compound influenced pain and inflammation scores in study participants. Available evidence remains limited regarding the compound's safety profile in general adult populations.

  • Clinical trials evaluated the effects of this combination on mobility and range of motion.
  • Researchers examined whether these changes correlated with the ability of study participants to perform certain daily activities.
  • The overall duration of the research period varied across the conducted studies.

Specific Study Findings

Trial 1: Assessment of Pain Scores (Phase III RCT)

This randomized, controlled trial (RCT) examined the compound's influence on the pain index over a 12-week period. Research protocols specified a fixed duration of compound administration for study participants.

  • Key Finding: The average pain score reduction observed in the group receiving the compound was compared to the score reduction in the placebo group.
  • Safety Profile: Adverse events reported by study participants were documented, and the incidence rate was compared against the control group.

Trial 2: Mobility and Inflammation Markers

This study evaluated the impact of the compound combination on joint inflammation markers and functional mobility metrics in a cohort of 250 individuals.

  • Key Finding: The study assessed changes in blood-based inflammation markers and the distance participants could walk in a set time.
  • Exploration of Compound Co-administration: Researchers documented findings related to the co-administration of the compound alongside other non-steroidal anti-inflammatory drugs (NSAIDs).

Summary and Conclusion

No direct comparative studies with other traditional treatments were evaluated. In summary, research has focused on the compound’s effects on measures relevant to chronic pain.

Key Studies & References

  1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf
  2. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain

Frequently Asked Questions (FAQ)

Common questions about Protecardin (FAQ)


Q: Are there any major diet restrictions while taking Protecardin?

Official documentation primarily advises that this medication be taken with or immediately after food to help with gastrointestinal tolerability. Regulatory cautions emphasize avoiding or strictly limiting alcohol consumption, as it significantly increases the risk of bleeding. Specific food groups are generally not listed as restricted in the official labeling.


Q: Is it normal to feel slightly dizzy when first starting Protecardin?

Dizziness is documented in official safety profiles as a possible adverse effect. Official safety information indicates that dizziness is a documented possible effect. If it occurs, particularly alongside other symptoms, regulatory guidance suggests seeking medical advice.


Q: Is there any difference between the generic and brand name Protecardin?

The active chemical substance in Protecardin is Acetylsalicylic acid (ASA). Regulatory bodies, such as the FDA and EMA, require that generic versions of a drug contain the exact same active ingredient. These generic medicines must also work in the same way and meet the same strict quality and strength requirements as the brand-name product.


Q: Does Protecardin affect blood pressure readings?

Official safety profiles for Acetylsalicylic acid have listed changes to blood pressure, such as hypotension (low blood pressure), as a possible adverse reaction. Additionally, existing medical conditions like high blood pressure are mentioned in regulatory warnings as a situation where caution may be required during use.


Q: Are there special considerations for people with kidney issues using Protecardin?

Official regulatory documents explicitly prohibit (contraindicate) the use of this medicine in patients who have severe renal impairment, which is a significant reduction in kidney function. Caution is also advised in patients with pre-existing kidney problems due to the risk of deterioration of kidney function.


Q: Can taking too much Protecardin cause long-term problems?

Overdose can lead to several serious symptoms, including rapid breathing, high fever, or seizures, and in the most severe cases, shock. Beyond overdose, official safety profiles link the highest risks of serious adverse reactions, particularly gastrointestinal ulceration and hemorrhage (severe bleeding), to the prolonged or chronic use of the medicine.


Q: Does Protecardin cause problems with sleep or insomnia?

Official safety profiles derived from regulatory data list several central nervous system effects as possible adverse reactions. These documented effects include trouble sleeping (insomnia) and unusual drowsiness, although the rate at which these occur is not specified in all documents.


Q: Can Protecardin be used by people who have had a stroke?

Official indications for the drug include its use for the secondary prevention of blood clot-related cerebrovascular disease. This means it is recognized for reducing the risk of death and nonfatal stroke in patients who have previously experienced an ischemic stroke or a transient ischemic attack (mini-stroke).


Q: Does the time of day I take Protecardin matter?

Official instructions specify that the drug is to be taken once daily and that the tablet must be swallowed whole with or immediately after food to aid tolerability. While the administration is tied to mealtime, the specific time of day (morning versus evening) is generally not mandated as a critical requirement in the regulatory label.


Q: How long does Protecardin stay in the system after the last dose?

The half-life of the active chemical substance, Acetylsalicylic acid (ASA), is very short, meaning it is quickly processed by the body. However, its intended antiplatelet effect is permanent for the affected blood platelets. Because platelets cannot repair themselves, this effect lasts for the entire duration of the platelet's lifespan, which is typically 7 to 10 days.


Q: What is the typical expectation for lifestyle changes needed with Protecardin?

The most explicit lifestyle-related caution detailed in official documents relates to alcohol use, noting that avoiding or strictly limiting consumption is advised because it significantly increases the risk of gastrointestinal bleeding associated with this medicine.


Q: Are there any known issues with Protecardin and dental procedures?

Official patient information advises informing your doctor or dentist if you are planning to have any surgical procedure, including a minor one like a tooth extraction. This is because the drug works to thin the blood and may increase the risk of bleeding during or after the procedure.


Q: Can I take a flu shot or other vaccines while on Protecardin?

Official drug interaction information notes a theoretical risk when certain vaccines (like the varicella virus vaccine) are administered to children or adolescents taking Acetylsalicylic acid. For routine adult vaccines, there is generally no mandatory contraindication stated in the official regulatory label.


Q: Does Protecardin cause any changes to mood or mental clarity?

Official safety profiles list central nervous system effects among the possible adverse reactions. These documented effects include symptoms such as confusion, nervousness, anxiety, and restlessness, although the rate at which they occur is not specified in all regulatory summaries.

How should Protecardin be stored and disposed of?

The storage and disposal of Protecardin (acetylsalicylic acid 75 mg gastro-resistant tablets) must adhere strictly to official regulatory conditions to ensure stability and environmental safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Do not store above 25 C.
Protection Store in the original container to protect from moisture.
Child Safety Keep out of the sight and reach of children.
Stability Do not use the product after the expiry date.

Disposal Instructions

Expired or unused medicine must not be thrown into household waste or flushed down the toilet. Disposal must follow local environmental regulations, typically requiring patients to return the product to a pharmacist for safe handling and destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Protecardin found in:

A-Z Index: